Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for...

Global Vutrisiran Market is set to surpass a revenue of US$ 2 Billion by 2033, expanding at a 12% CAGR during the forecast period | Data by Future Market Insights, Inc. NEWARK, Del, April 12, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Vutrisiran Market is expected to grow at a value of 12% CAGR, according to Future Market Insights. By the...

Praxis Precision Medicines to Present Data from Rare Disease Programs at the American Epilepsy Society 2021 Annual Meeting BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...